John Aballi Purchases 24,305 Shares of Exagen Inc. (NASDAQ:XGN) Stock

Exagen Inc. (NASDAQ:XGN) CEO John Aballi acquired 24,305 shares of Exagen stock in a transaction on Thursday, November 14th. The shares were bought at an average cost of $2.81 per share, with a total value of $68,297.05. Following the completion of the transaction, the chief executive officer now owns 689,799 shares of the company’s stock, valued at approximately $1,938,335.19. This trade represents a 3.65 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Exagen Stock Up 0.7 %

Shares of NASDAQ XGN traded up $0.02 during trading hours on Monday, reaching $3.00. 45,449 shares of the stock were exchanged, compared to its average volume of 41,877. The stock’s fifty day simple moving average is $2.82 and its 200 day simple moving average is $2.40. The company has a debt-to-equity ratio of 1.54, a current ratio of 4.05 and a quick ratio of 4.05. Exagen Inc. has a 52 week low of $1.30 and a 52 week high of $3.71.

Exagen (NASDAQ:XGN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.02. Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. The firm had revenue of $12.51 million for the quarter, compared to analysts’ expectations of $13.55 million. During the same quarter last year, the business earned ($0.31) EPS. On average, equities analysts forecast that Exagen Inc. will post -0.87 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Exagen

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Stonepine Capital Management LLC raised its stake in Exagen by 49.0% during the third quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock worth $1,651,000 after acquiring an additional 175,701 shares in the last quarter. Renaissance Technologies LLC grew its position in Exagen by 93.3% during the 2nd quarter. Renaissance Technologies LLC now owns 94,234 shares of the company’s stock worth $172,000 after acquiring an additional 45,476 shares during the last quarter. Creative Planning acquired a new position in shares of Exagen in the third quarter valued at approximately $110,000. Verus Capital Partners LLC acquired a new position in Exagen in the 3rd quarter valued at approximately $39,000. Finally, Palumbo Wealth Management LLC increased its holdings in Exagen by 14.5% in the third quarter. Palumbo Wealth Management LLC now owns 76,364 shares of the company’s stock valued at $236,000 after purchasing an additional 9,695 shares during the period. 75.25% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, William Blair reaffirmed an “outperform” rating on shares of Exagen in a report on Wednesday, November 13th.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).